Asceneuron develops symptomatic and disease-modifying drugs for the treatment of alzheimers disease and tauopathies.
Business Model:
Revenue: $8.9M
Employees: 11-50
Address: EPFL Innovation Park
City: Lausanne
State: vaud
Zip: 1015
Country: CH
Asceneuron develops symptomatic and disease-modifying drugs for the treatment of alzheimers disease and tauopathies.
Contact Phone:
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|
Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors | 3/2021 | Grant | $2.2M |
Alzheimer’s Drug Discovery Foundation |
5/2022 | Grant | - |
Michael J. Fox Foundation Michael J. Fox Foundation |
10/2016 | Grant | 1 | - |
Michael J. Fox Foundation Michael J. Fox Foundation |
9/2015 | Series A | 5 | $30.8M |
Johnson &a; Johnson Innovation SR One Sofinnova Partners M Ventures Kurma Partners Sofinnova Partners Johnson &a; Johnson Innovation SR One Sofinnova Partners M Ventures Kurma Partners Sofinnova Partners |
10/2016 | Grant | - | 9/2015 | Series A | $30.6M |
Sofinnova Partners SR One Kurma Partners MS Ventures |
10/2016 | Grant | - |
Michael J. Fox Foundation Michael J. Fox Foundation |
5/2022 | Grant | 1 | - |
Michael J. Fox Foundation Michael J. Fox Foundation |
10/2016 | Grant | 1 | - |
Michael J. Fox Foundation Michael J. Fox Foundation |
---|
Announced Date | Name | Price |
---|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|